Which groups are not suitable for taking Axitinib (Inlida) and description of drug risks

Axitinib (Axitinib) is an oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat advanced renal cell carcinoma. Although its efficacy is obvious, not all patients are suitable for use and it needs to be evaluated based on individual health conditions to avoid potential risks.

Axitinib should not be used in patients with severe hepatic or renal impairment. Since the drug is mainly metabolized by the liver and excreted in the urine, impaired liver and kidney function may cause the drug to accumulate in the body, thereby increasing the risk of toxic side effects such as hypertension, bleeding, or thrombotic events. Therefore, such patients need to have their liver and kidney function evaluated before use, and weigh the pros and cons under the guidance of a doctor.

Use with caution in patients with severe cardiovascular disease. Axitinib can cause cardiovascular adverse reactions such as hypertension, heart failure, or arrhythmia. The condition may be aggravated if the patient has a history of serious heart disease, such as coronary heart disease, heart failure, or uncontrolled high blood pressure. Therefore, such patients should undergo electrocardiogram and blood pressure monitoring before taking medication, and need to be reviewed regularly during treatment, and the dosage of medication should be adjusted in a timely manner.

In addition, pregnant and lactating women are also not suitable to take axitinib. Animal experiments show that the drug may cause harm to the fetus and affect the health of the baby through milk excretion. While using axitinib, patients should use effective contraception and fully communicate the risks with their doctor before treatment. At the same time, patients with bleeding tendencies or recent history of major surgery also need to use it with caution to reduce the incidence of drug-related complications.

Reference materials:https://www.drugs.com/